SCHEDULE 13G/A: Morgan Stanley Discloses Significant Stake in Stoke Therapeutics, Holding 6.5% of Common Stock

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.5% of Stoke Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Morgan Stanley, as a parent holding company, reported aggregate beneficial ownership of 3,426,739 shares of Stoke Therapeutics, Inc. common stock, representing 6.5% of the class.
• Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley, reported beneficial ownership of 2,879,280 shares, representing 5.4% of the class.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to previously reported beneficial ownership.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing the control of Stoke Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a major financial institution like Morgan Stanley is generally viewed as a positive signal of institutional confidence in the issuer, Stoke Therapeutics, Inc.

Positives

• The disclosure of a significant stake by a major financial institution like Morgan Stanley (6.5%) can be interpreted as a vote of confidence in Stoke Therapeutics, Inc.

Negatives

• The document does not contain information that would be considered negative regarding Stoke Therapeutics, Inc.'s operations or financial performance.

Risks

• The document does not detail specific risks related to Stoke Therapeutics, Inc.'s business operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

The document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates that Morgan Stanley, a prominent global financial services firm, holds a significant passive investment in Stoke Therapeutics, Inc. Such disclosures are routine for institutional investors when their beneficial ownership in a public company exceeds 5%, providing transparency to the market about major shareholder positions.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor sentiment and potentially stock price.
• Company Management: Awareness of a major institutional holder may influence strategic decisions, though the filing states the stake is passive.

Key Dates

Keywords

Stoke Therapeutics, Morgan Stanley, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Equity Stake